- June 29, 2022
- 12:05 PM - 1:00 PM ET
Tell us what you think about the town halls
The U.S. Food and Drug Administration (FDA) hosts regular virtual Town Halls for SARS-CoV-2 test developers. The purpose of these Town Halls is to help answer technical questions about the development and validation of tests for SARS-CoV-2. Registration is not necessary.
There will be an opportunity to ask questions live during the Town Halls, but questions may also be submitted in advance by emailing CDRHWebinars@fda.hhs.gov.
- Please submit questions by Monday 12 p.m. ET before the Wednesday virtual Town Hall.
- In the subject line of the email, state "Question for the COVID-19 Test Virtual Town Hall"
Save the Date:
The FDA will hold a virtual Town Hall for test developers from 12:05 p.m.-1 p.m. ET on:
- June 29: Town Hall #88
Add May and June Dates to My Calendar
Outlook users: Click link, select Open, then click Save & Close
- July 27: Town Hall #89*
- August 24: Town Hall #90*
*Webinar details to follow.
The FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases, including Coronavirus Disease 2019 (COVID-19). The FDA is committed to providing timely guidance to support response efforts to this pandemic.
The guidance "Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)" includes policies specific to this public health emergency.
The recording and transcript from the previous town halls are available for viewing.
Registration is not necessary.
Time: 12:05 p.m. - 1 p.m. ET
To ensure you are connected, please join 15 minutes before the start of the virtual Town Hall.
Please click the link below to join the webinar:
Please note: Participants who join the virtual Town Hall using the Zoom webinar link above should use computer audio (listen through their computer speakers and speaking through computer microphone/headset).
The dial-in information provided below is for participants who will be joining the virtual Town Hall by phone only.
Webinar ID: 160 403 9621
Following the webinar, a transcript, recording, and slides will be posted below.